Wall Street brokerages expect Jounce Therapeutics (NASDAQ:JNCE) to report ($0.31) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.38). Jounce Therapeutics posted earnings per share of ($0.02) in the same quarter last year, which suggests a negative year-over-year growth rate of 1,450%. The firm is expected to report its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Jounce Therapeutics will report full-year earnings of ($1.04) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($0.63). For the next year, analysts expect that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.81) to ($0.25). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Thursday, March 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.25. The firm had revenue of $13.00 million during the quarter, compared to the consensus estimate of $14.95 million. Jounce Therapeutics had a negative return on equity of 10.24% and a negative net margin of 22.76%. The company’s quarterly revenue was down 36.0% on a year-over-year basis. During the same period last year, the company earned $0.05 EPS.
Several research firms have weighed in on JNCE. Zacks Investment Research downgraded Jounce Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 8th. Robert W. Baird set a $35.00 target price on Jounce Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 8th.
Shares of NASDAQ:JNCE traded down $1.25 during midday trading on Friday, reaching $20.38. 172,823 shares of the company’s stock were exchanged, compared to its average volume of 351,208. The company has a market capitalization of $659.65, a price-to-earnings ratio of -35.76 and a beta of 6.33. Jounce Therapeutics has a fifty-two week low of $11.05 and a fifty-two week high of $29.29.
In other Jounce Therapeutics news, CEO Richard /Ca/ Murray sold 16,334 shares of Jounce Therapeutics stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $21.43, for a total value of $350,037.62. Following the completion of the transaction, the chief executive officer now directly owns 16,334 shares of the company’s stock, valued at approximately $350,037.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Barbara Gayle Duncan sold 2,000 shares of Jounce Therapeutics stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $28.11, for a total value of $56,220.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at $56,220. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,292 shares of company stock valued at $1,372,403.
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Jounce Therapeutics by 60.1% in the 4th quarter. BlackRock Inc. now owns 1,161,840 shares of the company’s stock valued at $14,812,000 after buying an additional 436,114 shares during the period. Redmile Group LLC boosted its stake in shares of Jounce Therapeutics by 2.6% in the 4th quarter. Redmile Group LLC now owns 980,393 shares of the company’s stock valued at $12,500,000 after buying an additional 24,795 shares during the period. Brown Advisory Inc. boosted its stake in shares of Jounce Therapeutics by 3.3% in the 4th quarter. Brown Advisory Inc. now owns 491,529 shares of the company’s stock valued at $6,267,000 after buying an additional 15,810 shares during the period. Alyeska Investment Group L.P. boosted its stake in shares of Jounce Therapeutics by 43.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 262,105 shares of the company’s stock valued at $4,084,000 after buying an additional 79,683 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Jounce Therapeutics by 310.4% in the 4th quarter. Millennium Management LLC now owns 246,021 shares of the company’s stock valued at $3,137,000 after buying an additional 186,068 shares during the period. Institutional investors and hedge funds own 90.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://transcriptdaily.com/2018/04/13/brokerages-expect-jounce-therapeutics-jnce-to-announce-0-31-eps.html.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.